New and emerging biomarkers of heart failure

Critical Reviews in Clinical Laboratory Sciences

Volumn 46, Issue 3, 2009, Pages 107-128

  Clerico, Aldo ^a   Vittorini, Simona ^b   Passino, Claudio ^a   Emdin, Michele ^b  

^a SCUOLA SUPERIORE SANT ANNA   (Italy)

^b FONDAZIONE TOSCANA GABRIELE MONASTERIO   (Italy)

Author keywords

Cardiac troponin; Cardiovascular biomarker; Evidence based laboratory medicine; Heart failure; Natriuretic peptides; Risk factor

Indexed keywords

ACTIN; ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANKYRIN; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CAVEOLIN 3; CONNECTIN; DESMIN; DESMOCOLLIN; DYSTROPHIN; ENALAPRIL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INWARDLY RECTIFYING POTASSIUM CHANNEL; LAMIN A; LAMIN C; LEPTIN; MYOSIN HEAVY CHAIN BETA; MYOSIN LIGHT CHAIN; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; TRANSFORMING GROWTH FACTOR BETA3; TROPONIN; TROPONIN I; TROPONIN T; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

ACUTE CORONARY SYNDROME; AMYLOIDOSIS; ANAMNESIS; ARTERIAL PRESSURE; BLOOD SAMPLING; BRUGADA SYNDROME; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CLINICAL DECISION MAKING; CONGESTIVE CARDIOMYOPATHY; DIAGNOSTIC ACCURACY; DNA POLYMORPHISM; DYSPNEA; ECHOCARDIOGRAPHY; EDEMA; ELECTROCARDIOGRAPHY; EXERCISE TEST; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; GENETIC ASSOCIATION; GOLD STANDARD; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE DYSPLASIA; HEART SOUND; HUMAN; JUGULAR VEIN; LABORATORY TEST; LONG QT SYNDROME; MARKER GENE; MYOCARDIAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN CONSUMPTION; PATIENT MONITORING; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SARCOIDOSIS; SCREENING TEST; STABLE ANGINA PECTORIS; URINALYSIS; WOLFF PARKINSON WHITE SYNDROME; CARDIOVASCULAR SYSTEM EXAMINATION;

BIOLOGICAL MARKERS; DIAGNOSTIC TECHNIQUES, CARDIOVASCULAR; HEART FAILURE; HUMANS;

EID: 68949218808     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.1080/10408360902722342     Document Type: Review

References (241)

1. NICE (National Institute of Clinical Excellence). Clinical Guideline 5. Chronic heart failure. Management of chronic heart failure in adults in primary and secondary care. pp 1-44. London, 2003
2. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Lévy S, Linde C, Lopez-Sendon JL, Nieminen MS, Piérard L, Remme WJ; Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115-1140
3. Nieminen MS, Böhm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, Hasin Y, Lopez-Sendon J, Mebazaa A, Metra M, Rhodes A, Swedberg K, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie MR, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Garcia MA, Dickstein K, Albuquerque A, Conthe P, Crespo-Leiro M, Ferrari R, Follath F, Gavazzi A, Janssens U, Komajda M, Morais J, Moreno R, Singer M, Singh S, Tendera M, Tygesen K;ESC Committee for Practice Guidelines (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 384-416 (Pubitemid 40283098)
4. Hunt SA; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46: e1-e82
5. Adams KF, Lindenfeld J, Arnold JMO, Baker DW, Barnard DH, Baughman KL. Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Cardiac Fail 2006; 12: 10-38
6. Braunwald E, Bristow MR. Congestive heart failure: ffty years of progress. Circulation 2000; 102(20 Suppl 4): IV14-IV23
7. Dipla K, Mattiello JA, Jeevanandam V, Houser SR, Margulies KB. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation 1998; 97: 2316-2322
8. Eichhorn EJ, Bristow MR. Medical therapy can improve the biologic properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 1996; 94: 2285-2296
9. Vittorini S, Clerico A. Cardiovascular biomarkers: increasing impact of laboratory medicine in cardiology practice. Clin Chem Lab Med 2008; 46: 748-763
10. Panteghini M. Role and importance of biochemical markers in clinical cardiology. Eur Heart J 2004; 25: 1187-1196
11. Macabasco-OïConnell A, Miller PS. Biomarkers for heart failure. Prog Cardiovasc Nurs 2006; 21: 215-218
12. De Virginy DR. Novel and potential future biomarkers for assessment of the severity and prognosis of chronic heart failure: a clinical review. Heart Fail Rev 2006; 11: 333-334
13. Vasan S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006; 113: 2335-2362
14. Lainscak M, von Haehling S, Springer J, Anker SD. Biomarkers for chronic heart failure. Heart Fail Monit 2007; 5: 77-82
15. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-2159
16. Biomarkers Defnition Working Group. Biomarkers and surrogate endpoints: preferred defnitions and conceptual framework. Clin Pharmacol Ter 2001; 69: 89-95
17. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: a review. Clin Chem 2004; 50: 33-50
18. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 2004; 164: 1978-1984
19. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure? A systematic review. Br Med J 2005; 330(7492): 625-627
20. Maisel AS, McCullough PA. Cardiac natriuretic peptides: a proteomic window to cardiac function and clinical management. Rev Cardiovasc Med 2003; 4(Suppl 4): S3-S12
21. Rays J, Wajngarten M, Gebara OC, Nussbacher A, Telles RM, Pierri H, Rosano G, Serro-Azul JB. Long-term prognostic value of triiodothyronine concentration in elderly patients with heart failure. Am J Geriatr Cardiol 2003; 12: 293-297
22. Pingitore A, Landi P, Taddei MC, Ripoli A, LïAbbate A, Iervasi G. Triiodothyronine levels for risk stratifcation of patients with chronic heart failure. Am J Med 2005; 118: 132-136
23. Pousset F, Isnard R, Komajda M. Prognostic value of neu-rohormones in heart failure in clinical practice. Arch Mal Coeur Vaiss 2002; 95: 27-32
24. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, Barlera S, Maggioni AP, Tognoni G, Cohn JN;For the Val-HeFT Investigators. Te comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004; 25: 292-299
25. Tsutamoto T, Sakai H, Tanaka T, Fujii M, Yamamoto T, Wada A, Ohnishi M, Horie M. Comparison of active renin concentration and plasma renin activity as a prognostic predictor in patients with heart failure. Circ J 2007; 71: 915-921 (Pubitemid 46833931)
26. Benedict CR, Shelton B, Johnstone DE, Francis G, Greenberg B, Konstam M, Probstfeld JL, Yusuf S. Prognostic signifcance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation 1996; 94: 690-697
27. Pousset F, Isnard R, Lechat P, Kalotka H, Carayon A, Maistre G, Escolano S, Tomas D, Komajda M. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 1997; 18: 254-258
28. Tsutamoto T, Hisanaga T, Fukai D, Wada A, Maeda Y, Maeda K, Kinoshita M. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol 1995; 76: 803-808
29. Frey B, Pacher R, Locker G, Bojic A, Hartter E, Woloszczuk W, Stanek B. Prognostic value of hemodynamic vs big endothe-lin measurements during long-term IV therapy in advanced heart failure patients. Chest 2000; 117: 1713-1719
30. Selvais PL, Robert A, Ahn S, van Linden F, Ketelslegers JM, Pouleur H, Rousseau MF. Direct comparison between endothelin-1, N-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure. J Card Fail 2000; 6: 201-207
31. Masson S, Latini R, Anand IS, Barlera S, Judd D, Salio M, Perticone F, Perini G, Tognoni G, Cohn JN; Val-HeFT Investigators. Te prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail 2006; 12: 375-380
32. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, Buttimore RC, Lainchbury JG, Elliott JM, Ikram H, Crozier IG, Smyth DW. Plasma N-terminal pro-brain natriuretic peptide and adrenomedul-lin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97: 1921-1929
33. Pousset F, Masson F, Chavirovskaia O, Isnard R, Carayon A, Golmard JL, Lechat P, Tomas D, Komajda M. Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure. Eur Heart Fail 2000; 21: 1009-1014
34. Rademaker MT, Cameron VA, Charles CJ, Lainchbury JG, Nicholls MG, Richards AM. Adrenomedullin and heart failure. Regul Pept 2003; 112: 51-60
35. Boonprasert P, Lailerd N, Chattipakorn N. Urocortins in heart failure and ischemic heart disease. Int J Cardiol 2008; 127: 307-312
36. Schulze PC, Kratzsch J. Leptin as a new diagnostic tool in chronic heart failure. Clin Chim Acta 2005; 362: 1-11
37. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, Hildebrandt P. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112: 1756-1762
38. Wannamethee SG, Whincup PH, Lennon L, Sattar N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 2007; 167: 1510-1517
39. Tsutamoto T, Tanaka T, Sakai H, Ishikawa C, Fujii M, Yamamoto T, Horie M. Total and high molecular weight adi-ponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 2007; 28: 1723-1730
40. Tamura T, Furukawa Y, Taniguchi R, Sato Y, Ono K, Horiuchi H, Nakagawa Y, Kita T, Kimura T. Serum adiponec-tin level as an independent predictor of mortality in patients with congestive heart failure. Circ J 2007; 71: 623-630
41. Cohen-Solal A, Barnier P, Pessione F, Seknadji P, Logeart D, Laperche T, Gourgon R. Comparison of the long-term prognostic value of peak exercise oxygen pulse and peak oxygen uptake in patients with chronic heart failure. Heart 1997; 78: 572-576 (Pubitemid 28034206)
42. Francis DP, Shamim W, Davies LC, Piepoli MF, Ponikowski P, Anker SD, Coats AJ. Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO2 slope and peak VO2. Eur Heart J 2000; 21: 154-161
43. Scharf C, Merz T, Kiowski W, Oechslin E, Schalcher C, Brunner-La Rocca HP. Noninvasive assessment of cardiac pumping capacity during exercise predicts prognosis in patients with congestive heart failure. Chest 2002; 122: 1333-1339
44. Guazzi M, De Vita S, Cardano P, Barlera S, Guazzi MD. Normalization for peak oxygen uptake increases the prognostic power of the ventilatory response to exercise in patients with chronic heart failure. Am Heart J 2003; 146: 542-548
45. Schalcher C, Rickli H, Brehm M, Weilenmann D, Oechslin E, Kiowski W, Brunner-La Rocca HP. Prolonged oxygen uptake kinetics during low-intensity exercise are related to poor prognosis in patients with mild-to-moderate congestive heart failure. Chest 2003; 124: 580-586
46. Passino C, Severino S, Poletti R, Piepoli MF, Mammini C, Clerico A, Gabutti A, Nassi G, Emdin M. Aerobic training decrease B-type natriuretic peptide expression and adrener-gic activation in patients with heart failure. J Am Coll Cardiol 2006; 47: 1835-1839
47. Ingle L. Prognostic value and diagnostic potential of cardi-opulmonary exercise testing in patients with chronic heart failure. Eur J Heart Fail 2008; 10: 112-118
48. Vitarelli A, Tiukinhoy S, Di Luzio S, Zampino M, Gheorghiade M. Te role of echocardiography in the diagnosis and management of heart failure. Heart Fail Rev 2003; 8: 181-189 (Pubitemid 36559674)
49. Tohan V. Prognostic implications of echocardiography in advanced heart failure. Curr Opin Cardiol 2004; 19: 238-249
50. Kirkpatrick JN, Vannan MA, Narula J, Lang RM. Echocardi-ography in heart failure: applications, utility, and new horizons. J Am Coll Cardiol 2007; 50: 381-396
51. Fernandes VR, Cheng S, Lima JA. Atherosclerosis imaging and heart failure. Heart Fail Rev 2006; 11: 279-288
52. Young JB. Imaging patients with heart failure: expectations of the clinician. Heart Fail Clin 2006; 2: 107-115
53. Butler J. Te emerging role of multi-detector computed tomography in heart failure. J Card Fail 2007; 13: 215-226
54. McVeigh E. Measuring mechanical function in the failing heart. J Electrocardiol 2006; 39(4 Suppl): S24-S27
55. Lauerma K. Magnetic resonance imaging of the failing heart. Scand J Surg 2007; 96: 102-106
56. Keenan NG, Pennell DJ. CMR of ventricular function. Echocardiography 2007; 24: 185-193
57. White JA, Patel MR. Te role of cardiovascular MRI in heart failure and the cardiomyopathies. Cardiol Clin 2007; 25: 71-95
58. Arrighi JA, Dilsizian V. Nuclear probes for assessing myo-cardial viability in heart failure. Heart Fail Clin 2006; 2: 129-143
59. Bengel FM. Positron emission tomography and magnetic resonance imaging in heart failure. J Nucl Cardiol 2006; 13: 145-149
60. Schinkel AF, Poldermans D, Elhendy A, Bax JJ. Assessment of myocardial viability in patients with heart failure. J Nucl Med 2007; 48: 1135-1146
61. Perna ER, Macín SM, Parras JI, Pantich R, Farías EF, Badaracco JR, Jantus E, Medina F, Brizuela M. Cardiac tro-ponin T levels are associated with poor short- and long-term prognosis in patients with acute cardiogenic pulmonary edema. Am Heart J 2002; 143: 814-820
62. Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003; 108: 833-838
63. Hudson MP, OïConnor CM, Gattis WA, Tasissa G, Hasselblad V, Holleman CM, Gaulden LH, Sedor F, Ohman EM. Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. Am Heart J 2004; 147: 546-552
64. Ralli S, Horwich TB, Fonarow GC. Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure. Am Heart J 2005; 150: 1220-1227
65. Sugiura T, Takase H, Toriyama T, Goto T, Ueda R, Dohi Y. Circulating levels of myocardial proteins predict future deterioration of congestive heart failure. J Card Fail 2005; 11: 504-509
66. Metra M, Nodari S, Parrinello G, Specchia C, Brentana L, Rocca P, Fracassi F, Bordonali T, Milani P, Danesi R, Verzura G, Chiari E, Dei Cas L. Te role of plasma biomark-ers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T. Eur J Heart Fail 2007; 9: 776-786
67. You JJ, Austin PC, Alter DA, Ko DT, Tu JV. Relation between cardiac troponin I and mortality in acute decompensated heart failure. Am Heart J 2007; 153: 462-470
68. Fonarow GC, Peacock WF, Horwich TB, Phillips CO, Givertz MM, Lopatin M, Wynne J. ADHERE Scientifc Advisory Committee and Investigators. Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE. Am J Cardiol 2008; 101: 231-237
69. Latini R, Masson S, Anand IS, Missov E, Carlson M, Vago T, Angelici L, Barlera S, Parrinello G, Maggioni AP, Tognoni G, Cohn JN; Val-HeFT Investigators. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007; 116: 1242-1249
70. George J, Patal S, Wexler D, Roth A, Sheps D, Keren G. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 2005; 150: 484-487
71. Jordán A, Roldán V, García M, Monmeneu J, de Burgos FG, Lip GY, Marin F. Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis. J Intern Med 2007; 262: 385-392
72. Yan AT, Yan RT, Spinale FG, Afzal R, Gunasinghe HR, Stroud RE, McKelvie RS, Liu PP. Relationships between plasma levels of matrix metalloproteinases and neurohor-monal profle in patients with heart failure. Eur J Heart Fail 2008; 10: 125-128
73. Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, Feng AN, Lin SJ, Young MS. Te prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure. Eur J Heart Fail 2003; 5: 507-516
74. Alonso-Martínez JL, Llorente-Diez B, Echegaray-Agara M, Olaz-Preciado F, Urbieta-Echezarreta M, González-Arencibia C. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 2002; 4: 331-336
75. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, Signorini S, Mocarelli P, Hester A, Glazer R, Cohn JN; Val-HeFT Investigators. C-reactive protein in heart failure: prognostic value and the efect of valsartan. Circulation 2005; 112: 1428-1434
76. Evrin PE, Nilsson SE, Oberg T, Malmberg B. Serum C-reactive protein in elderly men and women: association with mortality, morbidity and various biochemical values. Scand J Clin Lab Invest 2005; 65: 23-31
77. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293: 1609-1616
78. Michowitz Y, Arbel Y, Wexler D, Sheps D, Rogowski O, Shapira I, Berliner S, Keren G, George J, Roth A. Predictive value of high sensitivity CRP in patients with diastolic heart failure. Int J Cardiol 2008; 125: 347-351
79. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, Mabuchi N, Sawaki M, Kinoshita M. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of inter-leukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998; 31: 391-398
80. Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Kinoshita M. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1587-1593
81. Orús J, Roig E, Perez-Villa F, Paré C, Azqueta M, Filella X, Heras M, Sanz G. Prognostic value of serum cytokines in patients with congestive heart failure. J Heart Lung Transplant 2000; 19: 419-425
82. Sharma R, Rauchhaus M, Ponikowski PP, Varney S, Poole-Wilson PA, Mann DL, Coats AJ, Anker SD. Te relationship of the erythrocyte sedimentation rate to infammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2000; 36: 523-528
83. Chin BS, Blann AD, Gibbs CR, Chung NA, Conway DG, Lip GY. Prognostic value of interleukin-6, plasma viscosity, fbrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur J Clin Invest 2003; 33: 941-948
84. Valgimigli M, Ceconi C, Malagutti P, Merli E, Soukhomovskaia O, Francolini G, Cicchitelli G, Olivares A, Parrinello G, Percoco G, Guardigli G, Mele D, Pirani R, Ferrari R. Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) Study. Circulation 2005; 111: 863-870
85. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez M, Ferrer J. Prognostic value of interleukin-8 as a predictor of heart failure in patients with myocardial infarction and percutaneous intervention. Int J Cardiol 2006; 111: 158-160
86. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, Lee RT. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004; 109: 2186-2190
87. Januzzi JL Jr, Peacock W F, Maisel AS, Chae CU, Jesse RL, Baggish AL, OïDonoghue M, Sakhuja R, Chen AA, van Kimmenade RR, Lewandrowski KB, Lloyd-Jones DM, Wu AH. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) Study. J Am Coll Cardiol 2007; 50: 607-613
88. Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008; 54: 752-756
89. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, Sagara M, Kubota I. Pentraxin 3, a new marker for vascular infammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008; 155: 75-81
90. Emdin M, Pompella A, Paolicchi A. Gamma-glutamyl trans-ferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation 2005; 112: 2078-2080
91. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H; Vorarlberg Health Monitoring and Promotion Program Study Group. Gammaglutamyl transferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005; 112: 2130-2137
92. Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, Fox CS, Wang TJ, Benjamin EJ, DïAgostino RB, Vasan RS. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Tromb Vasc Biol 2007; 27: 127-133
93. Tsutsui T, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Ohnishi M, Kinoshita M. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardiol 2002; 39: 957-962
94. Sam F, Kerstetter DL, Pimental DR, Mulukutla S, Tabaee A, Bristow MR, Colucci WS, Sawyer DB. Increased reactive oxygen species production and functional alterations in anti-oxidant enzymes in human failing myocardium. J Card Fail 2005; 11: 473-480
95. Rojas A, Mercadal E, Figueroa H, Morales MA. Advanced glycation and ROS: a link between diabetes and heart failure. Curr Vasc Pharmacol 2008; 6: 44-51
96. Okonko DO, Crosato M, Kalra PR, Cicoira M, John M, Doehner W, Coats AJ, Poole-Wilson PA, Anker SD. Association of deranged adrenal steroid metabolism with anemia in chronic heart failure. Am J Cardiol 2005; 96: 101-103
97. Delafontaine P, Akao M. Angiotensin II as candidate of cardiac cachexia. Curr Opin Clin Nutr Metab Care 2006; 9: 220-224
98. Güder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G, Angermann CE, Störk S. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 2007; 115: 1754-1761
99. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci (Lond) 2007; 113: 267-278
100. Cicoira M, Kalra PR, Anker SD. Growth hormone resistance in chronic heart failure and its therapeutic implications. Card Fail 2003; 9: 219-226
101. Dreifuss P. Congestive heart failure and the growth hormone/insulin-like growth factor-1 (GH/IGF-1) system. Am J Cardiol 2003; 92: 245-246
102. Vasan RS, Sullivan LM, DïAgostino RB, Roubenof R, Harris T, Sawyer DB, Levy D, Wilson PW. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Intern Med 2003; 139: 642-648
103. Schulze PC, Späte U. Insulin-like growth factor-1 and muscle wasting in chronic heart failure. Int J Biochem Cell Biol 2005; 37: 2023-2035
104. Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M, Medras M, Anker SD, Banasiak W, Poole-Wilson PA, Ponikowski P. Anabolic defciency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006; 114: 1829-1837
105. Petretta M, Colao A, Sardu C, Scopacasa F, Marzullo P, Pivonello R, Fontanella L, de Caterina M, de Simone A, Bonaduce D. NT-proBNP, IGF-I and survival in patients with chronic heart failure. Growth Horm IGF Res 2007; 17: 288-296
106. Liggett SB, Wagoner LE, Craft LL, Hornung RW, Hoit BD, McIntosh TC, Walsh RA. Te Ile164 beta2-adrenergic receptor polymorphism adversely afects the outcome of congestive heart failure. J Clin Invest 1998; 102: 1534-1539
107. Wagoner LE, Craft LL, Singh B, Suresh DP, Zengel PW, McGuire N, Abraham WT, Chenier TC, Dorn GW 2nd, Liggett SB. Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure. Circ Res 2000; 86: 834-840
108. Forleo C, Resta N, Sorrentino S, Guida P, Manghisi A, De Luca V, Romito R, Iacoviello M, De Tommasi E, Troisi F, Rizzon B, Guanti G, Rizzon P, Pitzalis MV. Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomy-opathy. Am J Med 2004; 117: 451-458
109. Metra M, Zani C, Covolo L, Nodari S, Pezzali N, Gelatti U, Donato F, Nardi G, Dei Cas L. Role of beta1- and alpha2c-adrenergic receptor polymorphisms and their combination in heart failure: a case-control study. Eur J Heart Fail 2006; 8: 131-135
110. Andersson B, Blange I, Sylvén C. Angiotensin-II type 1 receptor gene polymorphism and long-term survival in patients with idiopathic congestive heart failure. Eur J Heart Fail 1999; 1: 363-369
111. Sanderson JE, Yu CM, Young RP, Shum IO, Wei S, Arumanayagam M, Woo KS. Infuence of gene polymorphisms of the renin-angiotensin system on clinical outcome in heart failure among the Chinese. Am Heart J 1999; 137: 653-657
112. Li Y, Zagato L, Kuznetsova T, Tripodi G, Zerbini G, Richart T, Tijs L, Manunta P, Wang JG, Bianchi G, Staessen JA. Angiotensin-converting enzyme I/D and alpha-adducin Gly460Trp polymorphisms: from angiotensin-converting enzyme activity to cardiovascular outcome. Hypertension 2007; 49: 1291-1297
113. Pilbrow AP, Palmer BR, Frampton CM, Yandle TG, Troughton RW, Campbell E, Skelton L, Lainchbury JG, Richards AM, Cameron VA. Angiotensinogen M235T and T174M gene polymorphisms in combination doubles the risk of mortality in heart failure. Hypertension 2007; 49: 322-327
114. Charron P, Tesson F, Poirier O, Nicaud V, Peuchmaurd M, Tiret L, Cambien F, Amouyel P, Dubourg O, Bouhour J, Millaire A, Juilliere Y, Bareiss P, André-Fouët X, Pouillart F, Arveiler D, Ferrières J, Dorent R, Roizès G, Schwartz K, Desnos M, Komajda M. Identifcation of a genetic risk factor for idiopathic dilated cardiomyopathy. Involvement of a polymorphism in the endothelin receptor type A gene. CARDIGENE Group. Eur Heart J 1999; 20: 1587-1591
115. Colombo MG, Ciofni E, Paradossi U, Bevilacqua S, Biagini A. ET-1 Lys198Asn and ET(A) receptor H323H polymorphisms in heart failure. A case-control study. Cardiology 2006; 105: 246-252
116. Vasku A, Goldbergová M, Hollá LI, Spinarová L, Spinar J, Vítovec J, Vácha J. Two MMP-2 promoter polymorphisms (-790T/G and -735C/T) in chronic heart failure. Clin Chem Lab Med 2003; 41: 1299-1303
117. Mizon-Gérard F, de Groote P, Lamblin N, Hermant X, Dallongeville J, Amouyel P, Bauters C, Helbecque N. Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction. Eur Heart J 2004; 25: 688-693
118. van der Meer P, De Boer RA, White HL, van der Steege G, Hall AS, Voors AA, van Veldhuisen DJ. Te VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT-HF Substudy. J Card Fail 2005; 11: 279-284
119. Liggett SB, Kelly RJ, Parekh RR, Matkovich SJ, Benner BJ, Hahn HS, Syed FM, Galvez AS, Case KL, McGuire N, Odley AM, Sparks L, Kardia SL, Dorn GW 2d. A functional polymorphism of the Galphaq (GNAQ) gene is associated with accelerated mortality in African-American heart failure Hum Mol Genet 2007 16 2740-2750
120. Sarzani R, Forleo C, Pietrucci F, Capestro A, Soura E, Guida P, Sorrentino S, Iacoviello M, Romito R, Dessì-Fulgheri P, Pitzalis M, Rappelli A. Te 212A variant of the APJ receptor gene for the endogenous inotrope apelin is associated with slower heart failure progression in idiopathic dilated cardio-myopathy. J Card Fail 2007; 13: 521-529
121. Vassalle C, Andreassi MG, Prontera C, Fontana M, Zyw L, Passino C, Emdin M. Infuence of ScaI and natriuretic peptide (NP) clearance receptor polymorphisms of the NP System on NP concentration in chronic heart failure. Clin Chem 2007; 53: 1886-1890
122. Marshall DA, OïBrien BJ. Economic evaluation of diagnostic tests. In Price PC and Christensen RH, Eds Evidence-based Laboratory Medicine-From Principles to Outcomes, Pp 159-186. Washington DC: AACC Press, 2003
123. Logeart D, Saudubray C, Beyne P, Tabut G, Ennezat PV, Chavelas C, Zanker C, Bouvier E, Solal AC. Comparative values of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. J Am Coll Cardiol 2002; 40: 1794-1800
124. Ogawa K, Oida A, Sugimura H, Kaneko N, Nogi N, Hasumi M, Numao T, Nagao I, Mori S. Clinical signifcance of blood brain natriuretic peptide level measurement in the detection of heart disease in untreated outpatients: comparison of electrocardiography, chest radiography and echocardiog-raphy. Circ J 2002; 66: 122-126
125. Dokainish H, Zoghbi WA, Lakkis NM, Quinones MA, Nagueh SF. Comparative accuracy of B-type natriuretic pep-tide and tissue Doppler echocardiography in the diagnosis of congestive heart failure. Am J Cardiol 2004; 93: 1130-1135
126. Nielsen OW, McDonagh TA, Robb SD, Dargie HJ. Retrospective analysis of the cost-efectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003; 41: 113-120
127. Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA, Stevenson LW, Shekelle PG. Cost-efectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 2004; 43: 1019-1026
128. Arques S, Roux E, Sbragia P, Ambrosi P, Taieb L, Pieri B, Gelisse R, Luccioni R. Accuracy of tissue Doppler echocar-diography in the emergency diagnosis of decompensated heart failure with preserved left ventricular systolic function: comparison with B-type natriuretic peptide measurement. Echocardiography 2005; 22: 657-664
129. Nakamura M, Tanaka F, Sato K, Segawa T, Nagano M. B-type natriuretic peptide testing for structural heart disease screening: a general population-based study. J Card Fail 2005; 11: 705-712
130. Steg PG, Joubin L, McCord J, Abraham WT, Hollander JE, Omland T, Mentré F, McCullough PA, Maisel AS. B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. Chest 2005; 128: 21-29
131. Aspromonte N, Ceci V, Chiera A, Coletta C, DïEri A, Feola M, Giovinazzo P, Milani L, Noventa F, Scardovi AB, Sestili A, Valle R. Rapid brain natriuretic peptide test and Doppler echocardiography for early diagnosis of mild heart failure. Clin Chem 2006; 52: 1802-1808
132. Dokainish H, Zoghbi WA, Ambriz E, Lakkis NM, Quinones MA, Nagueh SF. Comparative cost-efectiveness of B-type natriuretic peptide and echocardiography for predicting outcome in patients with congestive heart failure. Am J Cardiol 2006; 97: 400-403
133. Fuat A, Murphy JJ, Hungin AP, Curry J, Mehrzad AA, Hetherington A, Johnston JI, Smellie WS, Dufy V, Cawley P. Te diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract 2006; 56: 327-333
134. Mueller C, Laule-Kilian K, Schindler C, Klima T, Frana B, Rodriguez D, Scholer A, Christ M, Perruchoud AP. Cost-efectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med 2006; 166: 1081-1087 (Pubitemid 43765179)
135. Nakamura M, Sakai T, Osawa M, Onoda T, Yonezawa S, Okayama A, Hiramori K. Comparison of positive cases for B-type natriuretic peptide and ECG testing for identifcation of precursor forms of heart failure in an elderly population. Int Heart J 2005; 46: 477-487
136. Alehagen U, Svensson E, Dahlström U. Natriuretic peptide biomarkers as information indicators in elderly patients with possible heart failure followed over six years: a head-to-head comparison of four cardiac natriuretic peptides. J Card Fail 2007; 13: 452-461
137. Rutten FH, Cramer MJ, Zuithof NP, Lammers JW, Verweij W, Grobbee DE, Hoes AW. Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease. Eur J Heart Fail 2007; 9: 651-659
138. Lukowicz T V, Fischer M, Hense HW, Döring A, Stritzke J, Riegger G, Schunkert H, Luchner A; MONICA Investigators. BNP as a marker of diastolic dysfunction in the general population: importance of left ventricular hypertrophy. Eur J Heart Fail 2005; 7: 525-531
139. Bursi F, Weston SA, Redfeld MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA, Roger VL. Systolic and diastolic heart failure in the community. JAMA 2006; 296: 2209-2216
140. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, Levy D. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction. JAMA 2002; 288: 1252-1259
141. Emdin M, Clerico A, Clemenza F, Galvani M, Latini R, Masson S, Mulè P, Panteghini M, Valle R, Zaninotto M, Ganau A, Mariotti R, Volpe M, Aspromonte N, Cacciatore G, Cappelletti P, LïAbbate A, Miglio F, Ottani F, Pagani F, Passino C, Plebani M, Sarzani R, Zucchelli G; Italian Association of Hospital Cardiologists; Italian Society of Cardiology; Italian Federation of Cardiology; Italian Society of Clinical Chemistry and Molecular Biology; Italian Society of Laboratory Medicine; Italian Society of Emergency Medicine. Recommendations for the clinical use of cardiac natriuretic peptides. Ital Heart J 2005; 6: 430-446
142. Fraser CG. Inherent biological variation and reference values. Clin Chem Lab Med 2004; 42: 758-764
143. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC; Standards for Reporting of Diagnostic Accuracy. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for reporting diagnostic accuracy. Clin Chem 2003; 49: 1-6
144. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Moher D, Rennie D, de Vet HC, Lijmer JG; Standards for Reporting of Diagnostic Accuracy. Te STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 2003; 138: W1-W12
145. Deeks JJ. Systematic reviews of evaluation of diagnostic and screening tests. BMJ 2001; 323: 157-163
146. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specifcity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005; 58: 982-990
147. Pepe MS. Te Statistical Evaluation of Medical Tests for Classifcation and Prediction. New York: Oxford University Press, 2003
148. Sackett DL, Haynes RB. Te architecture of diagnostic research. BMJ 2002; 324: 539-541
149. Kattan MW. Evaluating a new markerïs predictive contribution. Clin Cancer Res 2004; 10: 822-824
150. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) Study. Circulation 2002; 105: 310-315
151. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetière P, Jousilahti P, Keil U, Njølstad I, Oganov RG, Tomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM; SCORE Project Group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE Project. Eur Heart J 2003; 24: 987-1003
152. Hense HW. Observations, predictions and decisions-assessing cardiovascular risk assessment. Int J Epidemiol 2004; 33: 235-239
153. Brotman DJ, Walker E, Lauer MS, OïBrien RG. In search of fewer independent risk factors. Arch Intern Med 2005; 165: 138-145
154. Cook NR. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem 2008; 54: 17-23
155. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007; 115: 928-935
156. Fonarow GC. Epidemiology and risk stratifcation in acute heart failure. Am Heart J 2008; 155: 200-207
157. Fonarow GC, Adams KF Jr, Abraham W T, Yancy CW, Boscardin WJ; ADHERE Scientifc Advisory Committee, Study Group, and Investigators. Risk stratifcation for in-hospital mortality in acutely decompensated heart failure: classifcation and regression tree analysis. JAMA 2005; 293: 572-580
158. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003; 290: 2581-2587
159. Cufe MS, Calif RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, OïConnor CM, Pina I, Quigg R, Silver MA, Gheorghiade M; Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287: 1541-1547
160. Clinical Quality Improvement Network Investigators. Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure. Te relative importance of age, sex, and medical therapy. Arch Intern Med 1996; 156: 1669-1673
161. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC; ADHERE Scientifc Advisory Committee and Investigators. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006; 47: 76-84
162. Felker GM, Leimberger JD, Calif RM, Cufe MS, Massie BM, Adams KF Jr, Gheorghiade M, OïConnor CM. Risk stratifcation after hospitalization for decompensated heart failure. J Card Fail 2004; 10: 460-466
163. Rector TS, Ringwala SN, Ringwala SN, Anand IS. Validation of a risk score for dying within 1 year of an admission for heart failure. J Card Fail 2006; 12: 276-280
164. Krumholz HM, Wang Y, Mattera JA, Wang Y, Han L F, Ingber MJ, Roman S, Normand SL. An administrative claims model suitable for profling hospital performance based on 30-day mortality rates among patients with heart failure. Circulation 2006; 113: 1693-1701 (Pubitemid 43754231)
165. May HT, Horne BD, Levy WC, Kfoury AG, Rasmusson KD, Linker DT, Mozafarian D, Anderson JL, Renlund DG. Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide. Am J Cardiol 2007; 100: 697-700
166. Valenstein PN. Evaluating diagnostic tests with imperfect standards. Am J Clin Pathol 1990; 93: 252-258
167. Fletcher RH, Fletcher SW. Clinical Epidemiology, 4th Ed. Pp 36-38. Baltimore: Lippincott Williams & Wilkins, 2005
168. Biesheuvel C, Irwig L, Bossuyt P. Observed diferences in diagnostic test accuracy between patient subgroups. Is it real or due to reference standard misclassifcations? Clin Chem 2007; 53: 1725-1729
169. Kraemer C. Evaluating Medical Tests: Objective and Quantitative Guidelines. Pp 1-296. Newbury Park, CA: Sage Publications 1992
170. Clerico A, Fontana M, Zyw L, Passino C, Emdin M. Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart aailure: a systematic review. Clin Chem 2007; 53: 813-822
171. Emdin M, Passino C, Prontera C, Fontana M, Poletti R, Gabutti A, Mammini C, Giannoni A, Zyw L, Zucchelli G, Clerico A. Comparison of brain natriuretic peptide (BNP) and amino-terminal proBNP for early diagnosis of heart failure. Clin Chem 2007; 53: 1264-1272
172. Jeyaseelan S, Goudie BM, Pringle SD, Donnan PT, Sullivan FM, Struthers AD. A critical re-appraisal of difer-ent ways of selecting ambulatory patients with suspected heart failure for echocardiography. Eur J Heart Fail 2007; 9: 55-61
173. Khunti K. Systematic review of open access echocardiogra-phy for primary care. Eur J Heart Fail 2004; 6: 79-83
174. Clarke KW, Gray D, Hampton JR. Evidence of inadequate investigation and treatment of patients with heart failure. Br Heart J 1994; 71: 584-587
175. Morise AP, Diamond GA. Comparison of the sensitivity and specifcity of exercise electrocardiography in biased and unbiased populations of men and women. Am Heart J 1995; 130: 741-747
176. Davie AP, Francis CM, Love MP, Caruana L, Starkey IR, Shaw TR, Sutherland GR, McMurray JJ. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ 1996; 312(7025): 222
177. Talwar S, Squire IB, Davies JE, Barnett DB, Ng LL. Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population. Eur Heart J 1999; 20: 1736-1744
178. Cardarelli R, Lumicao TG. B-type natriuretic peptide: a review of its diagnostic, prognostic, and therapeutic monitoring value in heart failure for primary care physicians. J Am Board Fam Pract 2003; 16: 327-333
179. Ng LL, Loke I, Davies JE, Khunti K, Stone M, Abrams KR, Chin DT, Squire IB. Identifcation of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography. Eur J Heart Fail 2003; 5: 775-782
180. Hedberg P, Lonnberg I, Jonason T, Nilsson G, Pehrsson K, Ringqvist I. Electrocardiogram and B-type natriuretic pep-tide as screening tools for left ventricular systolic dysfunction in a population-based sample of 75-year-old men and women. Am Heart J 2004; 148: 524-529
181. Choy AM, Darbar D, Lang CC, Pringle TH, McNeill GP, Kennedy NS, Struthers AD. Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods. Br Heart J 1994; 72: 16-22
182. Mak GS, DeMaria A, Clopton P, Maisel AS. Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function: comparison with tissue Doppler imaging recordings. Am Heart J 2004; 148: 895-902
183. Ewald B, Ewald D, Takkinstian A, Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Int Med J 2008; 38: 101-113
184. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, Perlini S, Obici L, Ascari E, dïEril GM, Moratti R, Merlini G. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amy-loidosis. Circulation 2003; 107: 2440-2445
185. Nordlinger M, Magnani B, Skinner M, Falk RH. Is elevated plasma B-natriuretic peptide in amyloidosis simply a function of the presence of heart failure? Am J Cardiol 2005; 96: 982-984
186. Yasutake H, Seino Y, Kashiwagi M, Honma H, Matsuzaki T, Takano T. Detection of cardiac sarcoidosis using cardiac markers and myocardial integrated backscatter. Int J Cardiol 2005; 102: 259-268
187. Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, Cinieri S, Martinelli G, Cipolla CM, Fiorentini C. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36: 517-522
188. Sandri MT, Cardinale D, Zorzino L, Passerini R, Lentati P, Martinoni A, Martinella A, Cipolla CM. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 2003; 49: 248-252
189. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM. Prognostic value of troponin I in cardiac risk stratifcation of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109: 2749-2754
190. Suzuki T, Hayashi D, Yamazaki T, Mizuno T, Kanda Y, Komuro I, Kurabayashi M, Yamaoki K, Mitani K, Hirai H, Nagai R, Yazaki Y. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998; 136: 362-363
191. Nousiainen T, Jantunen E, Vanninen E, Remes J, Puustinen J, Rantala A, Vuolteenaho O, Hartikainen J. Acute neurohu-moral and cardiovascular efects of idarubicin in leukemia patients. Eur J Haematol 1998; 61: 347-353
192. Nousiainen T, Jantunen E, Vanninen E, Remes J, Vuolteenaho O, Hartikainen J. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkinïs lymphoma. Eur J Haematol 1999; 62: 135-141
193. Okumura H, Iuchi K, Yoshida T, Nakamura S, Takeshima M, Takamatsu H, Ikeno A, Usuda K, Ishikawa T, Ohtake S, Matsuda T. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 2000; 104: 158-163
194. Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 2001; 37: 4-9
195. Pichon MF, Cvitkovic F, Hacene K, Delaunay J, Lokiec F, Collignon MA, Pecking AP. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. In Vivo 2005; 19: 567-576
196. Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, Leon M, Civelli M, Martinelli G, Cipolla CM. N-terminal pro-B-type natriuretic peptide after high-Dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 2005; 51: 1405-1410
197. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM. Prevention of high-dose chemotherapy-induced cardiotox-icity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114: 2474-2481
198. Prontera C, Fortunato A, Storti S, Mercuri A, Longombardo G, Zucchelli GC, Emdin M, Clerico A. Evaluation of analytical performance of the Siemens ADVIA TnI Ultra immunoassay. Clin Chem 2007; 53: 1722-1723
199. Clerico A, Fortunato A, Prontera C, Ripoli A, Zucchelli GC, Emdin M. Distribution of plasma cardiac troponin-I values in healthy subjects: pathophysiological considerations. Clin Chem Lab Med 2008; 46: 804-808
200. Swaanenburg JCJM, Visser-VanBrummen PJ, DeJongste MJL, Tiebosch ATHM. Te content and distribution of troponin I, troponin T, myogobin, and alpha-hydroxybutyric acid dehy-drogenase in the hunan heart. Am J Clin Pathol 2001; 115: 770-777
201. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AH, Christenson RH, Apple FS, Francis G, Tang W; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem 2007; 53: 552-574 (Pubitemid 46580223)
202. Anversa P, Leri A, Kajstura J, Nadal-Ginard B. Myocyte growth and cardiac repair. J Mol Cell Cardiol 2002; 34: 91-105
203. Clerico A, Recchia FA, Passino C, Emdin M. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 2006; 290: H17-H29
204. Wang TJ. Signifcance of circulating troponins in heart failure: if these walls could talk. Circulation 2007; 116: 1217-1220
205. Price CP. Evidence-based laboratory medicine: supporting decision making. Clin Chem 2000; 46: 1041-1050
206. Jourdain P, Jondeau G, Funck F, Guefet P, Le Helloco A, Donal E, Aupetit JF, Aumont MC, Galinier M, Eicher JC, Cohen-Solal A, Juillière Y. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007; 49: 1733-1739
207. Tygesen K, Alpert JS, White HD, Joint ESC/ACCF/ AHA/WHF Task Force for the Redefnition of Myocardial Infarction. Universal defnition of myocardial infarction. J Am Coll Cardiol 2007; 50: 2173-2195
208. Greely TH. Legal, ethical, and social issues in human genome research. Annu Rev Anthopol 1998; 27: 473-502
209. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E. Multimarker approach to risk stratifcation in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002; 105: 1760-1763
210. Spencer G. International Consortium Completes Human Genome Project. Bethesda, MD: National Institutes of Health, 2003
211. Gibbons GH, Liew CC, Goodarzi MO, Rotter JI, Hsueh WA, Siragy HM, Pratt R, Dzau VJ. Genetic markers: progress and potential for cardiovascular disease. Circulation 2004; 109: 47-58
212. Marban E. Translation, translation, translation. Circulation research in cardiologyïs new golden age. Circ Res 2005; 96: 4-5
213. Seo D, Ginsburg GS, Goldschmidt-Clermont PJ. Gene expression analysis of cardiovascular diseases: novel insights into biology and clinical applications. J Am Coll Cardiol 2006; 48: 227-235
214. Ginsburg GS, Haga SB. Translating genomic biomarkers into clinically useful diagnostics. Expert Rev Mol Diagn 2006; 6: 179-191
215. Weston AD, Hood L. System biology, proteomics, and the future of health care: toward predictive, preventive, and personalized medicine. J Proteome Res 2004; 3: 179-196
216. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabási AL. Te human disease network. Proc Natl Acad Sci USA 2007; 104: 8685-8690
217. Xue H, Wang S, Wang H, Sun K, Song X, Zhang W, Fu C, Han Y, Hui R. Atrial natruretic peptide gene promoter polymorphism is associated with left ventricular hypertrophy in hypertension. Clin Sci (Lond) 2008; 114: 131-137
218. Rubattu S, Bigatti G, Evangelista A, Lanzani C, Stanzione R, Zagato L, Manunta P, Marchitti S, Venturelli V, Bianchi G, Volpe M, Stella P. Association of atrial natriuretic peptide and type A natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol 2006; 48: 499-505
219. Kato N, Sugiyama T, Morita H, Nabika T, Kurihara H, Yamori Y, Yazaki Y. Genetic analysis of the atrial natriuretic peptide gene in essential hypertension. Clin Sci (Lond) 2000; 98: 251-258
220. Rubattu S, Ridker PM, Stampfer M, Hennekens CH, Volpe M, Lindpaintner K. Te gene encoding atrial natriuretic pep-tide and the risk of human stroke. Circulation 1999; 100: 1722-1726
221. Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Leiendecker-Foster C, Arnett DK. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. JAMA 2008; 299: 296-307
222. Rubattu S, Stanzione R, Di Angelantonio E, Zanda B, Evangelista A, Tarasi D, Gigante B, Pirisi A, Brunetti E, Volpe M. Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke 2004; 35: 814-818
223. Gruchala M, Ciecwiierz D, Wasag B, Targonski R, Dubaniewicz W, Nowak A, Sobiczewski W, Ochman K, Romanowski P, Limon J, Rynkiewicz A. Association of the Sca I atrial natriuretic peptide gene polymorphisms with nonfatal myocardial infarction and extent of coronary artery disease. Am Heart J 2003; 14: 125-131
224. Rutledge DR, Sun Y, Ross EA. Polymorphisms within the atrial natriuretic peptide gene in essential hypertension. J Hypertens 1995; 13: 953-955
225. Lanfear DE, Stolker JM, Marsh S, Rich MW, McLeod HL. Genetic variation in the B-type natriuretic peptide pathway afects BNP levels. Cardiovasc Drugs Ter 2007; 21: 55-62
226. Meirhaeghe A, Sandhu MS, McCarthy MI, de Groote P, Cottel D, Arveiler D, Ferrières J, Groves CJ, Hattersley AT, Hitman GA, Walker M, Wareham NJ, Amouyel P. Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations Hum Mol Genet 2007, 1, 1343-1350
227. Lajer M, Tarnow L, Jorsal A, Parving HH. Polymorphisms in the B-type natriuretic peptide (BNP) gene are associated with NT-proBNP levels but not with diabetic nephropathy or mortality in type 1 diabetic patients. Nephrol Dial Transplant 2007; 22: 3235-3239
228. Kosuge K, Soma M, Nakayama T, Aoi N, Sato M, Izumi Y, Matsumoto K. A novel variable number of tandem repeat of the natriuretic peptide precursor b geneïs 59-fanking region is associated with essential hypertension among Japanese females. Int J Med Sci 2007; 4: 146-152
229. Ono K, Mannami T, Baba S, Tomoike H, Suga S, Iwai N. A single-nucleotide polymorphism in C-type natriu-retic peptide gene may be associated with hypertension. Hypertens Res 2002; 25: 727-730
230. Nakayama T, Soma M, Takahashi Y, Rehemudula D, Sato M, Uwabo J, Izumi Y, Kanmatsuse K. Nucleotide sequences of the 59-fanking region of the type A human natriuretic pep-tide receptor gene and association analysis using a novel microsatellite in essential hypertension. Am J Hypertens 1999; 12: 1144-1148
231. Usami S, Kishimoto I, Saito Y, Harada M, Kuwahara K, Nakagawa Y, Nakanishi M, Yasuno S, Kangawa K, Nakao K. Association of CT dinucleotide repeat polymorphism in the 59-fanking region of the guanylyl cyclase (GC)-A gene with essential hypertension in the Japanese. Hypertens Res 2008; 31: 89-96
232. Knowles JW, Erickson LM, Guy VK, Sigel CS, Wilder JC, Maeda N. Common variations in noncoding regions of the human natriuretic peptide receptor A gene have quantitative efects. Hum Genet 2003; 112: 62-70
233. Nakayama T, Soma M, Saito S, Honye J, Sato M, Aoi N, Kosuge K, Haketa A, Kanmatsuse K, Kokubun S. Missense mutation of exon 3 in the type A human natriuretic peptide receptor gene is associated with myocardial infarction. Med Sci Monit 2003; 9: CR505-CR510
234. Nakayama Y, Soma M, Mizutani Y, Xinjuan X, Honye J, Kaneko Y, Rahmutula D, Aoi N, Kosuge K, Saito S, Ozawa Y, Kanmatsuse K, Kokubun S. A novel missense mutation of exon 3 in the type A human natriuretic peptide receptor gene: possible association with essential hypertension. Hypertens Res 2002; 25: 395-401
235. Pitzalis MV, Sarzani R, Dessì-Fulgheri P, Iacoviello M, Forleo C, Lucarelli K, Pietrucci F, Salvi F, Sorrentino S, Romito R, Guida P, Rappelli A, Rizzon P. Allelic variants of natriuretic peptide receptor genes are associated with family history of hypertension and cardiovascular phenotype. J Hypertens 2003, 21: 1491-1496
236. Nakayama T, Soma M, Takahashi Y, Rehemudula D, Kanmatsuse K, Furuya K. Functional deletion mutation of the 59-fanking region of type A human natriuretic peptide receptor gene and its association with essential hypertension and left ventricular hypertrophy in the Japanese. Circ Res 2000; 86: 841-845
237. Rehemudula D, Nakayama T, Soma M, Takahashi Y, Uwabo J, Sato M, Izumi Y, Kanmatsuse K, Ozawa Y. Structure of the type B human natriuretic peptide receptor gene and association of a novel microsatellite polymorphism with essential hypertension. Circ Res 1999; 84: 605-610
238. Sarzani R, Dessì-Fulgheri P, Salvi F, Serenelli M, Spagnolo D, Cola G, Pupita M, Giantomassi L, Rappelli A. A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower atrial natriuretic peptide and higher blood pressure in obese hypertensives. J Hypertens 1999; 17: 1301-1305
239. Rame JE, Drazner MH, Post W, Peshock R, Lima J, Cooper RS, Dries DL. Corin I555(P568) allele is associated with enhanced cardiac hypertrophic response to increased systemic after-load. Hypertension 2007; 49: 857-864
240. Dries DL, Victor RG, Rame JE, Cooper RS, Wu X, Zhu X, Leonard D, Ho SI, Wu Q, Post W, Drazner MH. Corin gene minor allele defned by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. Circulation 2005; 112: 2403-2410. 241.
241. Wu C, Wu F, Pan J, Morser J, Wu Q. Furin-mediated processing of pro-C-type natriuretic peptide. J Biol Chem 2003; 278: 25847-25852